Insight

Sep 6, 2024, 11:26

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes

International Urology Cancer Summit made the following post on X:

“Non-BRCA1/2 HRR mutations might benefit from PARP inhibitors when direct BRCA complex interaction. Intriguing the effectiveness of platinum across all cohorts.”

Authors: Laura S. Graham, MD, Nicholas C. Henderson, Olesia Kellezi, BS, Clara Hwang, MD, Pedro C. Barata, MD, Mehmet A. Bilen, MD, Deepak Kilari, MD, Michael Pierro, MD, Bicky Thapa, MD, Abhishek Tripathi, MD, George Mo, MD, Matthew Labriola, MD, Joseph J. Park, MD, Shoshana Rothstein, MD, Rohan Garje, MD, Vadim S. Koshkin, MD, Vaibhav G. Patel, MD, Tanya Dorff, MD, Andrew J. Armstrong, MD, Rana R. McKay, MD, Ajjai Alva, MD and Michael T. Schweizer, MD

DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes

Source: International Urology Cancer Summit/X

Abhishek Tripathi Ajjai Alva Andrew J. Armstrong Bicky Thapa BRCA mutations cancer Clara Hwang Deepak Kilari DNA-damaging therapies George Mo homologous recombination repair genes Joseph J. Park Laura S. Graham Matthew Labriola Mehmet A Bilen Michael Pierro Michael T Schweizer Nicholas C. Henderson Olesia Kellezi OncoDaily Oncology PARP inhibitors Pedro C Barata platinum-based therapy prostate cancer Rana R. McKay Rohan Garje Shoshana Rothstein Tanya Dorff Vadim S Koshkin Vaibhav G. Patel

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage